药明巨诺由中国制药领域龙头企业药明康德和全球细胞免疫治疗领域明星公司Juno Therapeutics, Inc.于2016年共同创立。药明巨诺深耕细胞免疫治疗领域，专注于打造血液癌症及实体瘤开发、制造和商业化突破性细胞免疫疗法的一体化治疗平台。
方达团队牵头合伙人为罗德源；天元团队牵头合伙人为傅思齐、郁岩、杨喻意；谢尔曼·思特灵团队牵头合伙人为Kyungwon (Won) Lee、华一春。
Shearman, Davis Polk lead on Chinese cell therapy developer’s $300 mln HK IPO
Shearman & Sterling, Fangda Partners and Tian Yuan Law Firm have advised Chinese cancer cell therapy developer JW Therapeutics on its $300 million IPO in Hong Kong, with Davis Polk & Wardwell and Commerce & Finance Law Offices counselling the joint sponsors and underwriters.
JW Therapeutics is a clinical stage cell therapy platform company, founded by Juno Therapeutics and WuXi AppTec in 2016, and focused on developing, manufacturing and commercialising breakthrough cell-based immunotherapies for hematological cancers and solid tumours.
The listing is the latest in the recent flurry of biotech IPOs in Hong Kong. Other recent issuers in the city include Simcere Pharmaceutical Group, JHBP (CY) Holdings and Everest Medicines.
The Fangda team on this transaction was led by partner Colin Law. The Tian Yuan team was led by partners Fu Siqi, Yu Yan and Yang Yuyi. The Shearman team was led by partners Kyungwon (Won) Lee and Max Hua.
The Commerce & Finance team was led by partner Wang Bo.
To contact the editorial team, please email ALBEditor@thomsonreuters.com.